RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results

Key Takeaways

• RenovoRx’s pharmacokinetic and pharmacodynamic data from Phase III TIGeR-PaC trial accepted for 2026 ASCO Annual Meeting presentation
• Data supports the company’s TAMP therapy platform using RenovoCath drug delivery device for locally advanced pancreatic cancer
• ASCO presentation will provide key insights into the targeted drug delivery approach for one of the most challenging cancer types

---

RenovoRx, Inc. (Nasdaq: RNXT) announced that pharmacokinetic and pharmacodynamic data from its ongoing Phase III TIGeR-PaC clinical trial has been accepted for presentation at the 2026 ASCO Annual Meeting. The Mountain View, California-based life sciences company is developing the TAMP™ therapy platform for locally advanced pancreatic cancer treatment.

TAMP Platform Advances Pancreatic Cancer Treatment

The accepted abstract represents a sub-study of RenovoRx’s pivotal Phase III TIGeR-PaC trial, which evaluates the company’s targeted approach to pancreatic cancer therapy. The TAMP (Targeted Ablative Molecular Perfusion) platform utilizes the FDA-cleared RenovoCath® device to deliver chemotherapy directly to pancreatic tumors.

Pancreatic cancer remains one of the most challenging malignancies to treat, with limited therapeutic options for locally advanced disease. Traditional systemic chemotherapy often fails to achieve adequate drug concentrations at the tumor site while causing significant systemic toxicity.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

RenovoCath Device Technology

The RenovoCath system represents a patented drug delivery approach designed to overcome the barriers of pancreatic cancer treatment. By enabling targeted drug delivery, the device aims to maximize therapeutic efficacy while minimizing systemic exposure and associated side effects.

The pharmacokinetic data being presented at ASCO will likely provide crucial insights into drug distribution, metabolism, and elimination when delivered via the RenovoCath system. Pharmacodynamic data will demonstrate the biological effects and therapeutic response to this targeted delivery approach.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Outlook

ASCO presentations often serve as catalysts for increased investor and clinical interest in novel cancer therapies. For RenovoRx, the acceptance of this abstract validates the scientific merit of their TAMP platform approach and provides a prestigious forum to showcase their Phase III trial progress.

The 2026 ASCO Annual Meeting will offer RenovoRx an opportunity to present detailed efficacy and safety data to the global oncology community, potentially influencing future treatment guidelines for locally advanced pancreatic cancer.

---

Frequently Asked Questions

What does this ASCO presentation mean for pancreatic cancer patients?

The presentation will showcase data on a targeted drug delivery approach that could potentially improve treatment outcomes for locally advanced pancreatic cancer while reducing side effects compared to traditional systemic chemotherapy.

When will the TAMP therapy platform be available to patients?

The therapy is currently in Phase III trials. If successful, RenovoRx would need to complete the trial, analyze results, and seek FDA approval, which typically takes several years from trial completion.

How does RenovoCath compare to existing pancreatic cancer treatments?

RenovoCath offers targeted drug delivery directly to pancreatic tumors, potentially achieving higher local drug concentrations while minimizing systemic toxicity compared to traditional intravenous chemotherapy approaches.

Related coverage

• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
• OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation
• Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026